TABLE 2.
Trial population disposition and demographic characteristicsa
| Characteristic | Value(s) for participants receiving: |
||
|---|---|---|---|
| Ritonavir | Ketoconazole | EE-LNG | |
| No. (%) of participants enrolled | 8 | 10 | 20 |
| Mean (range) age (yr) | 29.4 (21–46) | 34 (22–50) | 54 (42–65) |
| No. (%) of subjects by sex | |||
| Male | 8 (100) | 8 (80) | 0 |
| Female | 0 | 2 (20) | 20 (100) |
| No. (%) of participants by race | |||
| White | 8 (100) | 7 (70) | 18 (90) |
| Black or African-American | 0 | 3 (30) | 2 (10) |
| Mean (range) wt (kg) | 71.6 (57.0–85.0) | 78.6 (73.5–92.8) | 69.7 (53.3–81.3) |
| Mean (range) ht (cm) | 180.1 (174–187) | 175.7 (163.0–187.0) | 160.7 (153.0–175.0) |
| Mean (range) BMI (kg/m2) | 22.1 (17.8–25.1) | 25.6 (21.1–30.3) | 27.1 (21.0–31.1) |
| No. of participants who: | |||
| Completed the trial | 8 | 10 | 19 |
| Discontinued the trial | 0 | 0 | 1 |
a
None of the participants were infected with HIV. BMI, body mass index; HIV, human immunodeficiency virus.